Bluejay Diagnostics, Inc. Common Stock
BJDXBlueJay Diagnostics, Inc. (BJDX) is a biotechnology company focused on developing innovative diagnostic solutions for infectious diseases. The company's technology aims to enable rapid, accurate, and cost-effective detection of various pathogens, enhancing clinical decision-making and patient outcomes. Bluejay Diagnostics leverages advanced molecular and digital health methodologies to advance point-of-care testing and improve healthcare efficiency.
Company News
Bluejay Diagnostics, Inc. announced that an abstract related to its Symphony IL-6 Test has been accepted for presentation at the 2025 SAEM Annual Meeting. The presentation will focus on results from the SYMON-I pilot clinical study, which evaluated IL-6 as a prognosticator for sepsis patients.
ACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of a firm commitment underwritten public offering wi...
Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and are admitted to the intensive care unit (ICU). Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor o...
ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) shares rose sharply in today's pre-market trading after Jefferies upgraded the stock from Hold to Buy and raised its price target from $14 to $20. ZIM Integrated Shipping Services shares climbed 9.2% to $14.72 in pre-market trading. Here are some other stocks moving in pre-market trading. Gain...
ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of its previously announced public offering of 2,692,...
